Linear vs Fragment SPPS for Peptide Manufacturing

Linear vs Fragment SPPS for Peptide Manufacturing As demand for complex peptide APIs reaches unprecedented scales, manufacturers face a critical strategic question: is linear solid-phase peptide synthesis (SPPS) or a fragment-based approach the right choice for large-scale production of the target molecule? Fragment-based approaches have gained attention following high-profile successes, but Bachem’s experience shows they are not automatically superior. To find out […] As demand for complex peptide APIs reaches unprecedented scales, manufacturers face a critical strategic question: is linear solid-phase peptide synthesis (SPPS) or a fragment-based approach the right choice for large-scale production of the target molecule? Fragment-based approaches have gained attention following high-profile successes, but Bachem’s experience shows they are not automatically superior. To find out when – and whether – conjugation of SPPS-based fragments truly delivers advantages over optimized linear SPPS, we conducted a comprehensive feasibility study and cost evaluation on a commercially relevant GLP-1 receptor agonist. Download the case study to discover: How fragment approaches can lose their cost advantage when realistic manufacturing conditions are applied, even for longer peptides How epimerization risk can compound through process stages in ways that theoretical models cannot predict Why linear SPPS achieved superior yields and purity – outperforming all fragment strategies tested A practical decision framework for selecting the right peptide manufacturing approach for your program